Basic Compazine Information

• INN (International Nonproprietary Name): Prochlorperazine.
• Brand Names Available In United States: Compazine (brand discontinued in some countries), Compro, and various prochlorperazine generics from multiple manufacturers.
• ATC Code: N05AB04.
• Forms & Dosages: Tablets 5 mg and 10 mg (rarely 25 mg), suppositories 25 mg, injectable ampoules/vials 5 mg/mL and 12.5 mg/mL for IM/IV use, and oral solution/syrup commonly 5 mg/5 mL.
• Manufacturers In United States: Heritage Pharmaceuticals, Teva, Sandoz, Fresenius Kabi, Medochemie, and other generic producers supply prochlorperazine products in U.S. markets.
• Registration Status In United States: Prochlorperazine generics remain FDA-approved under several NDAs while the original Compazine brand has been discontinued in some regions; prochlorperazine is registered as a prescription medicine in major markets.
• OTC / Rx Classification: Prescription Only (Rx) in all major jurisdictions.
• Standard Dosages Per Condition: For severe nausea or vomiting, adults: 5–10 mg orally 3–4 times daily or 5–10 mg IM/IV once or twice daily; pediatric dosing example: ≈0.13 mg/kg orally every 6–8 hours (refer to labeling for age-specific guidance).
• Population Dosing Adjustments: Use lower doses in children and the elderly, reduce dose and monitor in liver or kidney impairment, and avoid routine use in children under 2 years or under 10 kg without specialist direction.
• Typical Treatment Durations: Nausea/vomiting — short courses often under 7 days; psychiatric indications — reassess at 2–4 weeks and limit long-term use to specialist supervision.
• Missed Dose Instructions: Take when remembered unless it is nearly time for the next dose; do not double doses.
• Overdose Management: Supportive care for CNS or respiratory depression, hypotension, and extrapyramidal reactions; activated charcoal if early; ICU-level monitoring as needed; no specific antidote.
• Storage & Transport Guidelines: Store at room temperature 15–30°C, protect from excessive moisture and light, and follow manufacturer preparation instructions for injectable forms.
• Absolute Contraindications: Known hypersensitivity to prochlorperazine or other phenothiazines, comatose patients or severe CNS depression, oral use in children under 2 years or under 10 kg without specialist approval, and patients with bone marrow depression.
• Common Side Effects: Drowsiness, dizziness, blurred vision, dry mouth, constipation, hypotension, photosensitivity, weight gain, and extrapyramidal symptoms such as tremor, dystonia, or akathisia.

Key Findings From Recent Trials

Are clinicians still using Compazine for nausea in the emergency department and beyond?

Recent randomized trials of prochlorperazine specifically since 2022 are limited, and most contemporary evidence comes from observational emergency-department comparative studies and meta-analyses grouping older phenothiazines.

Emergency-department protocols have trended toward low-dose dopamine antagonists for non-chemotherapy acute nausea because they are cost-effective and provide short-term relief comparable to ondansetron in many cohorts.

Across ED-based analyses, typical dosing of prochlorperazine (5–10 mg oral or IM) often produced rapid symptom relief and reduced the need for rescue antiemetics in multiple studies.

These analyses support the role of generic prochlorperazine and Compazine-formulation alternatives where ondansetron access is limited or cost is a concern.

Safety observations in recent reports emphasize extrapyramidal reactions and sedation as the most frequent adverse events linked to prochlorperazine use.

Elderly patients and those with hepatic impairment are consistently flagged for dose reduction and closer monitoring because of altered clearance and increased sensitivity.

Regulatory reminders point out that prochlorperazine is classified under ATC N05AB04 and is available in multiple dosage forms that influence onset and use patterns in acute care.

Evidence gaps remain, particularly modern head-to-head randomized trials comparing prochlorperazine with 5-HT3 antagonists for chemotherapy-induced nausea.

Clinical Mechanism Of Action

How does Compazine stop nausea and what causes the typical side effects?

In simple terms, prochlorperazine calms the brain centers that trigger vomiting and reduces overactive dopamine signaling that can drive psychotic symptoms.

Scientifically, prochlorperazine is a phenothiazine with a piperazine structure that antagonizes dopamine D2 receptors in the chemoreceptor trigger zone and in limbic and mesolimbic circuits.

The primary receptor action is D2 antagonism, and the drug also has weaker anticholinergic, antihistaminic, and alpha-adrenergic blocking activity.

Those secondary receptor effects help explain common adverse effects such as sedation, dry mouth, hypotension, and orthostatic symptoms seen with prochlorperazine tablets or injectable products.

The antiemetic effect is largely central via D2 blockade in the CTZ, making IM or IV routes especially useful when rapid onset is needed in severe vomiting.

Peripheral effects on gastrointestinal motility are less pronounced than with metoclopramide, so prochlorperazine is chosen for central antiemetic activity rather than prokinetic benefit.

Available formulations — tablets (5 mg, 10 mg), suppositories (25 mg), and injectables (5 mg/mL and 12.5 mg/mL) — determine onset and bioavailability, with parenteral administration producing faster control of symptoms.

Receptor Profile

Which receptors explain efficacy and side effects?

Prochlorperazine’s main therapeutic action comes from dopamine D2 receptor antagonism in central vomiting centers and antipsychotic circuits.

Weaker anticholinergic effects contribute to dry mouth and constipation seen with the compazine pill or syrup.

Antihistamine activity adds to sedation, while alpha-adrenergic blockade can cause hypotension and orthostatic dizziness.

Central Vs Peripheral Effects

Where does Compazine act to relieve nausea?

Central blockade of D2 receptors in the CTZ provides the antiemetic effect and is the reason IM or IV use works fast when oral absorption is unreliable.

Peripheral GI motility effects are limited compared with metoclopramide, so prochlorperazine is not the preferred agent when prokinetic action is specifically desired.

Scope Of Approved And Off-Label Use

When is Compazine officially indicated and when do clinicians reach for it off-label?

Regulatory approvals converge on severe nausea and vomiting and on psychotic disorders for prochlorperazine generics sold in the United States and elsewhere.

In the U.S., prochlorperazine generics are FDA-approved and are marketed in tablet, suppository, injectable, and syrup forms under multiple labels.

Off-label trends include emergency-department use for acute symptomatic relief of severe non-chemotherapy nausea and short-term treatment of migraine with vomiting when antiemetic control is required.

Prochlorperazine is also used as an adjunct in palliative-care nausea when 5-HT3 agents are unavailable or cost-prohibitive, leveraging inexpensive compazine alternatives or generics from major manufacturers.

Psychiatric dosing historically treated schizophrenia and acute psychosis with initial regimens such as 5–10 mg 3–4 times daily, though many psychiatrists now prefer atypical antipsychotics for long-term maintenance.

For pediatrics and older adults, caution is advised; pediatric dosing often follows weight-based rules (around 0.13 mg/kg every 6–8 hours), and clinicians avoid use in infants under 2 years or unter 10 kg without specialist oversight.

Across international health systems, prochlorperazine and Stemetil often remain prescription-only items and appear on some national essential medicines lists in resource-limited settings.

Dosage Strategy

How should compazine be dosed for nausea vs psychiatric conditions?

For adults with acute nausea and vomiting, oral dosing commonly uses 5–10 mg taken three to four times daily, and IM/IV doses of 5–10 mg are used once or twice daily in acute-care settings.

Short courses for nausea are typically limited to under seven days to reduce the risks of extrapyramidal symptoms and tardive effects with extended exposure.

For severe acute control in the emergency department, a single IM or IV dose of 5–10 mg often delivers rapid relief when oral absorption is unreliable.

Suppositories of 25 mg provide a useful alternative for patients who cannot tolerate oral or IV routes and are commonly used in hospice or postoperative care.

In schizophrenia or psychosis, older titration schemes began at 5–10 mg three to four times daily with specialist supervision and ceiling doses historically reported up to 150 mg/day, though modern practice favors lower maintenance doses under psychiatry oversight.

Short-term anxiety control sometimes uses 5 mg three to four times daily with a maximum of roughly 20 mg/day in selected cases, but routine use for anxiety is not the main indication.

Adjust doses downward in the elderly and in patients with hepatic or renal impairment, and avoid use in children under two years or below 10 kg unless a specialist prescribes otherwise.

If a dose is missed, take it when remembered unless it is nearly time for the next scheduled dose; do not double up to catch up.

Safety Protocols

Who should not take Compazine, and what side effects should patients watch for?

Absolute contraindications include known hypersensitivity to prochlorperazine or other phenothiazines, comatose patients or those with severe CNS depression, bone marrow depression, and oral use in children under two years or less than 10 kg without specialist approval.

Relative cautions include elderly patients (with an increased mortality signal in dementia-related psychosis), people with Parkinson’s disease, severe liver or kidney impairment, epilepsy due to a lowered seizure threshold, serious cardiovascular disease, and prior neuroleptic malignant syndrome.

Common adverse effects are drowsiness, dizziness, blurred vision, dry mouth, constipation, hypotension, photosensitivity, and weight gain.

Extrapyramidal symptoms such as tremor, acute dystonia, and akathisia are dose-dependent and are among the most clinically significant adverse events to monitor.

Overdose management focuses on supportive care for CNS and respiratory depression, hypotension, and extrapyramidal reactions, with activated charcoal considered if ingestion is recent; there is no specific antidote.

Clinicians should monitor for tardive dyskinesia during prolonged therapy and counsel patients to report involuntary movements, severe muscle stiffness, or respiratory difficulty immediately.

• Important: Avoid prolonged unsupervised therapy and reassess regularly when used for psychiatric indications.

Interaction Mapping

Can food or other medicines change how Compazine works?

There are no major food-drug contraindications specified, but oral absorption may be unreliable if vomiting is ongoing, which is why IM/IV or suppository forms are preferred in those situations.

Prochlorperazine adds to central nervous system depression when combined with alcohol, benzodiazepines, opioids, and other sedatives, increasing the risk of excessive sedation or respiratory depression.

Co-administration with other QT-prolonging medications warrants caution because susceptible patients could experience cardiac effects.

Avoid combining multiple strong D2 antagonists unless under specialist supervision due to additive extrapyramidal risks.

Use caution when prescribing with drugs that lower the seizure threshold, and monitor hepatic function because clearance may be reduced in liver disease, prompting dose adjustment.

In elderly or psychiatric polypharmacy, watch for increased extrapyramidal effects when prochlorperazine is used alongside other antipsychotics and for cumulative anticholinergic burden when combined with antimuscarinics.

When parenteral parings are necessary in hospital settings, perform ECG and hemodynamic monitoring if multiple interacting agents are present.

Patient Experience Analysis

What do patients say about compazine on forums and in ED surveys?

Quantitative ED surveys typically report high immediate satisfaction for nausea relief after a single IM/IV dose of 5–10 mg, especially in settings where ondansetron access is limited by cost.

Patient-reported adverse events commonly include sedation, restlessness or akathisia, and transient extrapyramidal reactions that often prompt calls for clearer pre-treatment counseling.

Forum discussions and palliative-care boards frequently praise the 25 mg suppository option when oral intake is not possible, noting rapid onset and affordability of generic prochlorperazine products.

Negative patient narratives often revolve around involuntary movements or stiffness after longer exposures, underscoring the clinical advice to limit antiemetic courses and to monitor with prolonged psychiatric use.

Clinicians commonly advise informed consent conversations about the risk of extrapyramidal symptoms, discuss alternatives such as ondansetron or metoclopramide, and outline management strategies for side effects like anticholinergic medications for acute dystonia.

Distribution & Pricing Landscape

Where does Compazine come from and how much will it cost compared with newer antiemetics?

Prochlorperazine is widely available as generics supplied by Heritage, Teva, Sandoz, Fresenius Kabi, Medochemie, and many local producers worldwide.

The Compazine brand has been discontinued in some markets, but generics and alternate brands like Compro and Stemetil continue to supply the market.

Generic competition keeps per-unit cost low, making tablets and injectable vials inexpensive relative to newer agents such as ondansetron.

Suppository forms (25 mg) are commonly cost-effective choices in hospice and postoperative care where oral or IV access is impractical.

Distribution is robust even in low- and middle-income settings because of widespread manufacturing, although occasional shortages for specific parenteral formulations can occur.

Hospitals and emergency departments frequently list prochlorperazine on formulary as an on-formulary, low-cost antiemetic used for acute control and cost containment decisions.

In the United States prochlorperazine is generally prescription-only, but in our online pharmacy, compazine is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

What are the main alternatives and how do they compare to Compazine?

Ondansetron, a 5-HT3 antagonist, is often first-line for chemotherapy- or postoperative-induced nausea because it has a low risk of extrapyramidal symptoms and is well tolerated, but it is usually costlier than generic prochlorperazine.

Metoclopramide offers prokinetic benefits useful for gastroparesis-related nausea, but it shares an extrapyramidal risk profile similar to prochlorperazine.

Promethazine is another phenothiazine with stronger sedative properties and IV vesicant risk, and it is inexpensive but often avoided intravenously for safety reasons.

Haloperidol can be an effective antiemetic in certain ED protocols but may carry higher QT and extrapyramidal risks compared with prochlorperazine.

Choosing between these options depends on clinical context: the route needed, patient comorbidities, relative risk of EPS, and cost considerations.

Comparison Snapshot

Ondansetron: Pros — well tolerated, low EPS risk; Cons — higher cost.

Metoclopramide: Pros — prokinetic effects; Cons — EPS risk comparable to prochlorperazine.

Promethazine: Pros — sedating and cheap; Cons — strong sedation and IV safety concerns.

Haloperidol: Pros — potent in some protocols; Cons — higher QT and EPS concerns.

Prochlorperazine: Pros — multiple routes, low cost, rapid relief; Cons — EPS risk and contraindications in vulnerable populations.

Regulatory Status

Is compazine still approved and what labeling cautions should clinicians note?

Prochlorperazine is globally registered as a prescription-only medicine and classified under ATC code N05AB04.

In the United States prochlorperazine generics remain FDA-approved while the original Compazine brand has been discontinued in some areas, though multiple generic approvals persist.

In Europe and other jurisdictions, prochlorperazine formulations such as Stemetil are authorized and may appear on national essential medicines lists.

Regulatory advisories emphasize contraindications, including hypersensitivity and use in comatose patients, and highlight safety signals such as increased mortality when antipsychotics are used in dementia-related psychosis among the elderly.

Parenteral preparations require sterile handling and adherence to labeling for storage and dilution instructions, and hospital formularies typically define monitoring requirements for long-term psychiatric use and antiemetic duration limits.

Consolidated FAQ

What is Compazine?

Compazine is the brand name historically used for prochlorperazine, a phenothiazine antiemetic and antipsychotic available in tablets 5 mg and 10 mg, suppositories 25 mg, injectable vials, and syrup formulations.

How fast does it work?

IM or IV doses typically begin to work within minutes to an hour, and oral tablets usually take about 30 to 60 minutes for noticeable effect.

What are common side effects?

Common side effects include drowsiness, extrapyramidal symptoms such as tremor or dystonia, dry mouth, and hypotension.

Who should avoid it?

Avoid in patients with known phenothiazine allergy, comatose patients, infants under two or under 10 kg for oral use unless directed by a specialist, and in those with bone marrow depression.

Can I take it with alcohol?

No — combining prochlorperazine with alcohol increases sedation and respiratory depression risk.

How should it be stored?

Store at room temperature between 15 and 30°C, and protect tablets, syrups, and suppositories from excessive moisture and light.

Is Compazine still available?

The branded Compazine product has been discontinued in some countries, but generic prochlorperazine and other brands such as Compro or Stemetil remain widely available.

Visual Guide

What quick-reference images and flow charts should clinicians and patients have on hand?

Create a dosage quick-chart showing tablet options 5 mg and 10 mg, suppository 25 mg, and injectable strengths 5 mg/mL and 12.5 mg/mL, and highlight typical adult nausea dosing of 5–10 mg orally three to four times daily or 5–10 mg IM/IV once or twice daily.

Include a mechanism infographic showing CTZ D2 blockade leading to antiemetic effect, with callouts for EPS risk and hypotension.

Provide a simple route decision flow: ongoing vomiting → choose IM/IV or suppository; mild outpatient nausea → oral tablet or syrup.

Add a quick safety strip listing contraindications like hypersensitivity and comatose states and monitoring flags for elderly and hepatic impairment.

Label images with common brand and generic names such as Compazine, Compro, Stemetil, and widely seen packaging to reduce dispensing errors.

Storage & Transport

How should Compazine be handled in the pharmacy and during shipping?

Store prochlorperazine at controlled room temperature between 15 and 30°C and protect products from excessive moisture and light.

Tablets, syrup, and suppositories tolerate standard pharmacy storage, while injectable vials require sterile handling, correct labeling, and adherence to manufacturer dilution instructions.

For transport, a cold chain is not required, but humidity-protected packaging is recommended in hot or tropical climates to reduce degradation risk for suppositories and syrups.

Consult the specific product monograph for shelf-life and batch-level expiry, and discard or return any compromised parenteral stock to ensure sterility.

Regulatory shipping paperwork should accompany cross-border distribution for traceability and pharmacovigilance when required.

Guidelines For Proper Use

What practical steps reduce risks and improve outcomes when prescribing Compazine?

Use prochlorperazine for nausea and vomiting as a short course, typically under seven days, and counsel patients on side effects and when to seek urgent care for rigid muscles, breathing problems, or severe sedation.

Choose IM/IV dosing of 5–10 mg for rapid control in acute settings, and use the 25 mg suppository for patients with vomiting who cannot take oral tablets.

For psychiatric indications, prescribe under specialist oversight, start with low doses such as 5–10 mg three to four times daily, reassess at two to four weeks, and avoid prolonged unsupervised therapy because of tardive dyskinesia risk.

Adjust doses in elderly patients and those with hepatic or renal impairment, and avoid use in children under two years or under 10 kg without specialist direction.

Document informed consent about the risk of extrapyramidal symptoms and discuss alternative options like ondansetron and metoclopramide where appropriate.

In cases of suspected overdose or severe reactions, provide supportive care and escalate to ICU monitoring as needed; activated charcoal may be appropriate if ingestion is recent.

Delivery Across United States